Company: TAK
Filing Date: 2025-06-25
Form Type: 20-F
Source: 0001395064-25-000095
Chunk: 135

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-06-25
Form: 20-F
Item: Item 5
Chunk 135
---
 year ended March 31, 2025; cost of sales includes expenses related to the unwinding of acquisition accounting adjustments (i. e., step up) in value of PP& E associated with the Shire acquisition completed in the fiscal year ended March 31, 2019.

                                                                           For the Year Ended March 31, 2024                                                                                                                                                                             
                                                                           Reported                                            Amortization of intangible assets      Impairment of intangible assets      Other operating income/expenses (2)      Others      Core Financial Measures  
                                                                           (IFRS)                                                                                                                                                                               (non-IFRS)               
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
                                                                           (billions of yen)                                                                                                                                                                                             
  Revenue                                                                  ¥                                      4,263.8      ¥                                      ¥                                    ¥                                        ¥           ¥                        
  Cost of sales                                                            (1,426.7)                                           —                                      —                                    —                                        0.4         (1,426.3)                
  Selling, general and administrative expenses                             (1,053.8)                                           —                                      —                                    —                                        0.9         (1,053.0)                
  Research and development expenses                                        (729.9)                                             —                                      —                                    —                                        0.3         (729.6)                  
  Amortization of intangible assets associated with products               (521.5)                                             521.5                                  —                                    —                                        —           —                        
  Impairment losses on intangible assets associated with products (1)      (130.6)                                             —                                      130.6                                —                                        —           —                        
  Other operating income (expenses)                                        (187.1)                                             —                                      —                                    187.1                                    —           —                        
  Operating profit                                                         ¥                                        214.1      ¥                                      ¥                                    ¥                                        ¥           ¥                        

___________

Notes:

(1) Intangible assets associated with products include in-process R& D (IPR& D).

(2) Other operating income/expenses include changes in fair value of financial assets and liabilities associated with contingent consideration arrangements, gains/losses on sales of property, plant and equipment and investment property, gain on divestment of business and subsidiaries, donations and contributions, rental income and lease expense for sublease, restructuring expenses, valuation reserves for pre-launch inventories, impairment of assets held for sale, legal provisions and write